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Abstract
Background. Cystic lesions of the pancreas are being identified more frequently. Deciding which asymptomatic lesions can
be safely followed with serial imaging and which require resection due to malignant potential is an increasingly common
question. Current clinical practice is to rely on characteristics of the lesions on CT scan, and additional information from
endoscopic ultrasound with fine-needle aspiration (EUS-FNA) and cyst fluid analysis or endoscopic retrograde
pancreatography (ERCP) to assess malignant potential. Hypothesis. The malignant potential of pancreatic cystic lesions
cannot be accurately predicted by CT scan. Methods. CT scans from 48 patients with cystic lesions of the pancreas were
stripped of patient identifiers and retrospectively presented to two expert radiologists. The radiologists recorded specific
characteristics of the lesions thought to be important in the differential diagnosis and their opinion of the likely diagnosis.
Diagnostic accuracy was assessed by comparing the radiologists’ diagnoses to the final pathologic diagnosis after resection.
To determine if clinical history, EUS-FNA or ERCP findings improved diagnostic accuracy, medical records were
retrospectively reviewed and scored as either supporting or not supporting malignant potential of the lesion. Results. Specific
diagnoses based on CT findings alone were correct in an average of 39% of the cases. Even when diagnoses were
dichotomized as benign (43%) or potentially malignant (57%, papillary mucinous neoplasms, mucinous cystic neoplasms,
cancer), determinations based on CT alone were accurate in an average of 61% of cases. Accuracy rates were 60.4 and
62.5% for the two radiologists, although there was only fair agreement between them (Kappa0.28, 95% CI(0.01
0.55), p0.05). When all clinical information available was considered together as a single dichotomous indicator of
malignant potential, the indicator was accurate in 90% of the cases (Kappa0.73, 95% CI(0.510.95, pB0.0001)).
Conclusion. Specific preoperative diagnosis of pancreatic cystic neoplasms by CT alone is substantially inaccurate.
Complementary tests such as EUS-FNA with fluid analysis and ERCP should be recommended to improve diagnosis
especially if nonoperative treatment is planned.
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Introduction
In the past, cystic neoplasms of the pancreas were
thought to be relatively uncommon, and a general
recommendation existed that all suspected cystic
neoplasms of the pancreas should be resected [13].
In recent years, with the widespread use of modern
CT, the identification of incidental asymptomatic
cysts of the pancreas has increased markedly. One
autopsy study demonstrated that small cystic lesions
were present in almost half of the patients studied and
the prevalence increased with age [4]. Many surgeons
now believe that some of these lesions can be safely
observed, especially in the elderly patient that may not
be an ideal operative candidate. The problem facing
surgeons is how to distinguish benign lesions, such as
pseudocysts and serous cystadenomas from malignant
or premalignant mucinous lesions such as mucinous
cystic neoplasms (MCN), and intraductal papillary
mucinous neoplasms (IPMN). In the current study,
we sought to determine the accuracy of high-quality
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modern CT scan with expert interpretation in the
diagnosis of cystic lesions of the pancreas. Based on
our clinical experience, we hypothesized that despite
rapid advancements in imaging quality, the accurate
diagnosis of pancreatic cystic lesions remains challen-
ging.
Methods
The present study is a retrospective blinded analysis of
48 consecutive cases with a preoperative diagnosis of
pancreatic cystic neoplasm who presented to our
Pancreas Center over a 32-month period (November
2004July 2007) for a surgical consultation. Patients
with a clear history of acute pancreatitis and sub-
sequent development of a pseudocyst were excluded
from the study. Patients diagnosed preoperatively with
solid pancreatic neoplasms with no cystic component
were also excluded from the study. Patients diagnosed
with a cystic neoplasm that have not undergone
resection were also excluded.
Preoperative CT scans from 48 patients with cystic
lesions of the pancreas were stripped of patient
identifiers, recorded on CD-ROM, and retrospec-
tively presented to two expert radiologists. Both
radiologists were fellowship-trained, and board certi-
fied by the American Board of Radiology. Each
radiologist had at least seven years experience as an
attending, dedicated, full-time abdominal CT imager.
The two radiologists reviewed the CT scans indepen-
dently. The radiologists filled out data sheets which
recorded the presence or absence of specific charac-
teristics of the lesions thought to be important in the
differential diagnosis, and their opinion of the most
likely diagnosis. The location of the lesion within the
pancreas and its greatest dimension as measured by
the radiologist were recorded. The structure of the
cyst was documented including a description of
the contour of the wall (lobulated or smooth), the
thickness of the cyst wall, the presence and thickness
of septae, and whether the cyst was unilocular or
multilocular. The presence and location within the
cyst of calcifications was noted as was the presence or
absence of a central scar. The presence or absence of a
solid component to the lesion was also recorded. The
radiologist was then asked to choose only one of the
following diagnoses that they considered the most
likely: serous cystadenoma, mucinous cystic neo-
plasm, intraductal papillary mucinous neoplasm, or
pseudocyst. The radiologist was allowed to select
‘‘other’’ and write in a specific diagnosis if none of
the previous selections were thought to be most likely.
Diagnostic accuracy was assessed by comparing the
radiologists’ diagnoses to the final pathologic diag-
nosis after resection. Agreement between the two
expert radiologists was assessed by Kappa statistics.
To determine the increase in sensitivity for detecting
malignant potential with additional information be-
yond CT findings, a more thorough review of each
case was performed. Using our prospective database,
the clinical history was reviewed along with endo-
scopic ultrasound with fine-needle aspiration (EUS-
FNA), or endoscopic retrograde pancreatography
(ERCP) findings. FNA results including the presence
of atypical cells, mucin, or cyst fluid CEA level 200
ng/mL were evaluated. An experienced surgeon then
considered all of this information along with the two
radiologist’s diagnoses and categorized the lesion as
benign, or of malignant potential. This opinion was
also compared to the final pathologic diagnosis after
resection.
Results
Among the 48 patients with cystic neoplasms in this
series, the majority (69%) were women (33 women,
15 men). The mean age was 60 years, but patients
with neuroendocrine tumors tended to be younger
with a mean age of 48. Most (81%) of the patients
were symptomatic which is not surprising in this
surgical series (Table I). The most common symptom
was pain (71%), and patients who had weight loss
tended to also have nausea or vomiting. Three of the
four patients with jaundice in this series had adeno-
carcinoma.
Specific diagnoses based on CT findings alone were
correct in an average of 39% of the cases (Table II and
III). Even when diagnoses were dichotomized by the
Table I. Symptoms.
Pathologic diagnosis N Symptomatic N (%) Jaundice N (%) Pain N (%) Wt. Loss N (%) N/va N(%)
Adenocarcinoma 11 11 (100) 3 (27) 9 (82) 4 (36) 6 (55)
IPMNb 9 6 (67) 0 (0) 5 (56) 2 (22) 2 (22)
Serous cystadenoma 7 6 (86) 0 (0) 6 (86) 2 (29) 2 (29)
Mucinous cystic neoplasms 8 6 (75) 0 (0) 5 (63) 2 (25) 2 (25)
Pseudocyst 6 6 (100) 1 (17) 6 (100) 1 (17) 4 (67)
PENc 5 3 (60) 0 (0) 2 (40) 1 (20) 0 (0)
Pseudopapillary carcinoma 1 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Hemorrhagic cyst 1 1 (100) 0 (0) 1 (100) 0 (0) 1 (100)
aN/V: Nausea and vomiting.
bIntraductal papillary mucinous neoplasm.
cPancreatic endocrine neoplasm.
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Table II. Radiologist #1 interpretation.
Location
Size
(mm) Septations Unilocular/Multilocular
Cyst wall thickness
(mm) Calcifications Central scar Lobulated/Smooth
Solid
component Rad. 1 Pathologic diagnosis
1 Tail 11 A U 3 A A S P Adenocarcinoma Serous cystadenoma
2 Tail 16 A U 2 A A S A Pseudocyst Pseudocyst
3 Tail 43 6 M 2 A A L P Adenocarcinoma Pseudopapillary
carcinoma
4 Tail 57 A U 3 Peripherally A S A Serous cystadenoma MCN
5 All 24 A M 3 A A L A Serous cystadenoma PEN
7 Head 21 A U 1 Peripherally A S A IPMN IPMN
9 All 27 1 M 2 Peripherally A L A IPMN IPMN
10 Head 44 3 M 2 Peripherally A L A IPMN MCN
11 Head 29 2 M 2 A A L A Serous cystadenoma IPMN
12 Tail 125 3 M 7 A A L P MCN Adenocarcinoma
13 Body 31 3 M 4 A A L P Adenocarcinoma IPMN
14 Head 8 A M 1 A A S A IPMN Adenocarcinoma
15 Body 33 5 M 8 A A L P Adenocarcinoma Adenocarcinoma
16 All 10 A U 1 A A L A IPMN Adenocarcinoma
17 Tail 120 A U 2 Peripherally A S A Pseudocyst Pseudocyst
18 Tail 17 1 M 4 A A S A Serous cystadenoma PEN
19 Tail 23 1 U 1 A A S A Serous cystadenoma MCN
20 Head 14 1 U 2 A A S A Serous cystadenoma PEN
21 Head 22 A U 1 A A S A IPMN IPMN
22 Tail 68 A M 2 A A L P MCN Adenocarcinoma
23 Tail 44 A M 3 Centrally and peripherally P L P Serous cystadenoma Serous cystadenoma
24 Head 65 A U 1 A A L A IPMN Pseudocyst
25 Body 51 2 M 2 A A S P MCN MCN
26 Tail 9 A L A A A L A Serous cystadenoma PEN
27 Tail 100 6 M 5 Peripherally A L A MCN MCN
28 Head 120 5 M 5 Centrally A L A Serous cystadenoma Serous cystadenoma
29 All 155 10 M 10 A A L P Adenocarcinoma Adenocarcinoma
30 Body 27 2 M 1 A A S A Pseudocyst PEN
31 Tail 51 4 M 6 Peripherally A S A Pseudocyst Pseudocyst
32 Head 14 A U 1 A A S A Pseudocyst Pseudocyst
33 Tail 60 3 M 2 A A L P MCN Adenocarcinoma
34 Head 14 1 M 1 A A S A Serous cystadenoma IPMN
35 Head 26 A U 6 A A L P Adenocarcinoma Adenocarcinoma
36 Tail 48 2 M 1 A A L P Serous cystadenoma Serous cystadenoma
37 Tail 15 2 M 1 A A S A MCN MCN
38 Head 110 A U A A A S A Adenocarcinoma IPMN
39 Tail 69 A U 2 A A S A Cyst/Lymphangioma Hemorrhagic cyst
with fibrosis
40 Head 32 10 M A A P L A MCN Serous cystadenoma
42 Body 38 3 M 9 A A L P Adenocarcinoma Adenocarcinoma
43 Head 30 1 M 2 A A L A IPMN IPMN
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radiologist as benign (radiologist 1: 39.6% vs. radi-
ologist 2: 45.8%) or potentially malignant/malignant
(radiologist 1: 60.4% vs. radiologist 2: 54.2%; IPMN,
MCN, cancer), determinations of malignant potential
based on CTalone were accurate in an average of 61%
of the cases (Tables II and III). Accuracy rates were
60.4% for radiologist 1 and 62.5% for radiologist 2,
although there was only fair agreement between
radiologists (Kappa0.28, 95% CI(0.010.55),
p0.05).
After resection (42 cases) or biopsy (six cases), the
majority (71%) of the cystic lesions in this series were
determined to be of malignant potential or malignant.
There were 11 cases (23%) with adenocarcinoma.
One additional patient had carcinoma in situ (CIS)
arising in a mucinous cystic neoplasm. Serum CA 19-
9 and/or CEA were elevated in seven out of 11 cases
(64%) with adenocarcinoma but both were normal in
the remaining cases except for one patient with an
IPMN who had a serum CEA of 4.9 ng/mL. Eleven
(23%) of the patients had EUS in addition to CT and
eight (73%) of these exams included FNA. When all
clinical information available including the clinical
history, radiologist’s interpretations, ERCP and EUS-
FNA results were considered together as a single
dichotomous indicator of malignant potential, the
indicator was accurate in 90% of the cases with
substantial agreement (Kappa0.73, 95% CI
(0.510.95), pB0.0001) (Table IV).
In this series of 48 patients with cystic neoplasms of
the pancreas, 18 premalignant lesions (MCN, IPMN)
were resected and cured, theoretically preventing the
development of cancer in some cases. Thirteen benign
lesions: six serous cystadenomas, six pseudocysts and
one hemorrhagic cyst were resected. All of these
lesions were causing symptoms. There were five
patients with a pancreatic endocrine neoplasm who
would be expected to have a prolonged survival.
Among the 11 patients with adenocarcinoma, the
outcome was poor as expected (Table V).
Among 38 patients who had a pancreas resection,
exocrine insufficiency developed in 13 patients
(34%), and endocrine insufficiency developed in six
patients (16%). Comparing patients who had a
Whipple vs. distal pancreatectomy, no difference in
terms of endocrine insufficiency was detected (p
0.402, Fisher’s exact test) but a significant difference
in exocrine insufficiency was observed (p0.035,
Fisher’s exact test) (Table VI).
Discussion
Cystic neoplasms of the pancreas may be more
frequent than previously recognized and are being
identified with increasing frequency as the use
of abdominal CT scanning has increased. Some of
these neoplasms undergo malignant transformation
and thus represent an opportunity to surgically cure
or prevent pancreatic adenocarcinoma. PancreaticT
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Table III. Radiologist #2 interpretation.
Location Size (mm) Septations
Unilocular/
Multilocular
Cyst wall
thickness (mm) Calcifications Central scar Lobulated/Smooth Solid comp. Rad. 2 Pathologic diagnosis
1 Tail 14 1 M 2 A A L A Serous cystadenoma Serous cystadenoma
2 Head 21 2 M 2 Centrally and peripherally A L A Serous cystadenoma Pseudocyst
3 Tail 43 2 U 1 A A S P MCN Pseudopapillary carcinoma
4 Tail 55 A U 2 A A S A Pseudocyst MCN
5 Head 26 1 M 0.5 A A L A IPMN PEN
7 Head 25 A U B1 A1 A S A IPMN IPMN
9 Head 30 B1 M 1 A A L A IPMN IPMN
10 Head 50 1.5 M B1 Centrallyand peripherally A L A Serous cystadenoma MCN
11 Head 31 B1 M B1 A A L A IPMN IPMN
12 Tail 122 1.5 M 2.5 A A S A Pseudocyst Adenocarcinoma
13 Body 33 1 M 2 A A L A IPMN IPMN
14 Head 20 B1 M 1.5 A A L A IPMN Adenocarcinoma
15 Body 30 1 U 2 A A S A MCN Adenocarcinoma
16 Head 15 B1 M 1.5 A A L A IPMN Adenocarcinoma
17 Tail 123 A U B1 A A S A Pseudocyst Pseudocyst
18 Body 40 A 2.2 A A S A MCN PEN
19 Tail 28 A U 1 A A S A Pseudocyst MCN
20 Head 17 A U 2 A A S A Pseudocyst PEN
21 Head 27 A U B1 A A S A IPMN IPMN
22 Body 27 A U ! A A L A Pseudocyst Adenocarcinoma
23 Tail 48 B1 M 1.5 Peripherally A L A Serous cystadenoma Serous cystadenoma
24 Head 28 A 1 A A S A Pseudocyst Pseudocyst
25 Body 50 2 U 2 A A L A MCN MCN
26 Tail 12 A U 1 A A L A Serous cystadenoma PEN
27 Tail 60 A U 12 A A S P Pseudocyst MCN
28 Head 130 1 M 2 Centrally and peripherally P L A Serous cystadenoma Serous cystadenoma
29 Tail 35 2 M 1 A A L A IPMN Adenocarcinoma
30 Body 25 A U 1 A A L A Pseudocyst PEN
31 Tail 60 A U 1.5 Peripherally A S A Pseudocyst Pseudocyst
32 Head 15 1 M 2 A A L A IPMN Pseudocyst
33 Tail 60 2 U 1.5 A A S A Pseudocyst Adenocarcinoma
34 Head 12 2 M 1 A A L A Serous cystadenoma IPMN
35 Head 25 A M 2 A A L A IPMN Adenocarcinoma
36 Tail 45 2 M 1 A A S A IPMN Serous cystadenoma
37 Tail 13 2 U 1 A A S A Serous cystadenoma MCN
38 Head 100 2 M 1 A A L A IPMN IPMN
39 Tail 75 A U B1 A A S A Pseudocyst Hemorrhagic cyst with fibrosis
40 Body 32 1 M 1 A P L A IPMN Serous cystadenoma
42 Body 38 4 M A A S A IPMN Adenocarcinoma
43 Head 26 1 M 1 A A L A IPMN IPMN
44 Head 22 4 M 2 A A L A Serous cystadenoma MCN
45 Body 36 2 M 3 A A L A MCN MCN
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cancer usually presents in an advanced stage due to a
delay in diagnosis and the overall five-year survival is
5%. Therefore, considering the current safety of
pancreatic resection, it is not surprising that there
has been an increase in the number of operations for
pancreatic cystic lesions [5]. However, some cystic
lesions of the pancreas are benign or slow growing and
the true rate of malignant transformation is unclear.
The dilemma for the surgeon is an accurate
assessment of the risk benefit ratio of resection versus
observation of these lesions in individual patients.
Radiologic features including the size of the lesion and
its growth rate, the density of the lesion, character-
istics of the wall such as nodules, septations, or
calcifications, and the relationship between the lesion
and the pancreatic duct have been proposed as criteria
that can help categorize these lesions.
Although a thorough history and radiographic
findings often suggest a particular diagnosis, EUS-
guided FNA and analysis of cyst fluid or ERCP
provide useful additional information to guide clinical
decision making. Cysts that contain thick fluid with
mucin, elevated CEA, or atypical cells must be treated
as potentially malignant. CEA appears to be the most
useful tumor marker to measure in pancreatic cyst
fluid [6]. The cut-off value for benign versus poten-
tially malignant varies in the literature, however,
about 200 ng/mL seems to provide optimal specificity
without significantly impacting sensitivity [68]. On-
going studies of molecular analysis of pancreatic cyst
fluid, particularly genetic analysis, may improve
diagnostic specificity in the future.
When considering the cost of care, the value of
multiple diagnostic tests to achieve the most accurate
preoperative diagnosis must be considered. The
current literature suggests that as many as 75% of
cystic pancreatic lesions are asymptomatic incidental
findings [9]. Although asymptomatic pancreatic cysts
are being discovered with increasing frequency, some
patients present with symptoms of biliary obstruction,
pancreatitis, or abdominal pain. Patients who are
symptomatic, such as those in this series, generally
proceed to surgical resection. In this surgical series,
81% of the patients presented with symptomatic
lesions. In symptomatic patients with CT findings of
a cystic neoplasm, further characterization of the
lesion with EUS-FNA, or ERCP is probably not
cost-effective. However, of the 39 patients in our
series with symptomatic lesions, 11 (28%) still had
either EUS-FNA, ERCP, or both prior to surgical
referral.
Also important in the cost considerations is the
long-term expense of serial CT scans and EUS-FNA
in cases where observation is recommended. This is
particularly true for younger patients. However,
surgery is not without its long-term costs. Calculating
the cost of managing exocrine or endocrine pancreatic
insufficiency after pancreatic resection is difficult. In
our series, although the incidence of endocrineT
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dysfunction after resection was relatively low, about a
third of the patients required chronic pancreatic
enzyme supplementation after surgery, particularly
after the Whipple procedure.
The value of resection is removal of a symptomatic
lesion or a malignant or potentially malignant lesion.
Of the lesions in our surgical series 39 (81%) were
symptomatic and 34 (71%) were determined to be
malignant or of malignant potential after resection.
Series with asymptomatic lesions may not be compar-
able. Other series have reported that only 20% of
resected asymptomatic pancreatic cysts have malig-
nant pathology [10]. Little is known about the natural
history of asymptomatic pancreatic cysts without
features suggesting malignant potential. During the
32-month time period of this study we encountered
eight additional patients with asymptomatic cysts who
were excluded from the present study because they
were observed rather than resected. All patients had
small lesions, B3 cm, underwent EUS-FNA and had
no mucin-producing or atypical cells, and cyst fluid
CEA B200 ng/mL. Our algorithm is to repeat CT
imaging at three-month intervals for the first year then
yearly for at least five years. Repeat EUS-FNA of the
cyst is performed if the lesion enlarges. Although we
would advise operative management in patients with
cysts that become symptomatic, enlarging cysts, or
cysts with new fluid analysis suggesting malignant
potential, none of the eight patients have come to
surgery after a mean follow-up of 18 months. Walsh
et al. reported their results with a similar treatment
algorithm for asymptomatic pancreatic cysts [8]. They
followed 98 patients for a mean of 24 months and only
four patients came to operation for increasing size
and/or development of symptoms. One was a muci-
nous cystic neoplasm (initial cyst fluid CEA was 896
ng/mL). Pathology on the other patients was benign
(lymphoepithelial cyst, pseudocyst, and serous cysta-
denoma) indicating that it may be safe to follow
asymptomatic lesions using this algorithm.
In our study, the latest CT equipment and techni-
ques combined with expert interpretation allowed an
accurate specific diagnosis in only 39% and accurate
prediction of malignant potential in 61%. This is
consistent with the 2560% range for diagnostic
accuracy of CT for cystic neoplasms reported in the
literature [1113]. The diagnostic accuracy of CT
diminishes in small unilocular lesions that are seen
more commonly in asymptomatic patients that are
more likely to be treated nonoperatively. In our study,
accuracy rates were 60.4 and 62.5% for the two
radiologists, although there was only fair agreement
on each case between radiologists (Kappa0.28,
95% CI(0.010.55), p0.05). Poor interobserver
consensus of the etiology of cystic pancreatic lesions
has been reported in other studies [14]. Recent
studies have also reported similar diagnostic accuracy
rates for MRI and CT in the characterization of cystic
pancreatic masses as benign or malignant [15].
Conclusion
Our data, and the literature, support the opinion that
CT alone is not sufficient in determining the malig-
nant potential of pancreatic cystic lesions. If a non-
operative approach is chosen, repeat imaging must be
combined with further analysis such as EUS-FNA
with analysis of cyst fluid.
Table IV. Prediction of malignant potential.
Radiologist #1 Radiologist #2 Multidisciplinary opinion Final pathology
Benign 19 22 11 14
Malignant/Malignant potential 29 26 37 34
Table V. Outcome in malignant cases.
Stage Surgery Status
Length of
follow-up
(months)
14 IB Whipple NED 15
16 IIB Whipple NED 17
22 IIB Whipple DEAD 29
35 IIB Whipple RECURRED 22
49 IIA Distal NED 13
56 IIB Whipple NED 13
Locally advanced or metastatic
unresectable
12 III None DEAD 24
15 IV None DEAD 2
29 IV None DEAD 6
33 IV None DEAD 21
42 IV None DEAD 8
Table VI. Pancreas function after resection of cystic neoplasms.
Surgery
Whipple N18 Distal N17 P*
Endocrine insufficiencya, n (%)
Yes 2 (11) 4 (24) 0.402
No 16 (89) 13 (76)
Exocrine insufficiencyb, n (%)
Yes 10(56) 3 (18) 0.035
No 8 (44) 14 (82)
*P-value were based on Fisher’s exact test.
aRequiring insulin or oral hypoglycemics six or more months
following resection.
bRequiring pancreatic digestive enzymes six or more months
following resection.
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